OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers-Reference-Cited by-同舟云学术

OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers

Published:2023-08-22 Issue:9 Volume:43 Page:709-717
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Bagger Yu,Ravis William R.,Harris Geoff,Bukofzer Stan^ORCID

Funder

Ferring Pharmaceuticals

Ocelot Bio, Inc.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-023-01299-y.pdf

Reference24 articles.

1. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014–48. https://doi.org/10.1002/hep.31884.

2. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105(1):229–36. https://doi.org/10.1016/0016-5085(93)90031-7.

3. Gines P, Sola E, Angeli P, Wong F, Nadim MK, Kamath P. Hepatorenal syndrome. Nat Rev Dis Primers. 2018;4(1):23. https://doi.org/10.1038/s41572-018-0022-7.

4. Harper D, Chandler B. Splanchnic circulation. BJA Educ. 2016;16:66–71.

5. Moller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int. 2018;38(4):570–80. https://doi.org/10.1111/liv.13589.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury;Hepatology;2024-02-14